Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2370646
Max Phase: Preclinical
Molecular Formula: C52H76N12O10S2
Molecular Weight: 1093.39
Molecule Type: Unknown
Associated Items:
ID: ALA2370646
Max Phase: Preclinical
Molecular Formula: C52H76N12O10S2
Molecular Weight: 1093.39
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCOc1ccc(C[C@H]2NC(=O)CC3(CCCCC3)SCSC[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](Cc3ccccc3)NC2=O)cc1
Standard InChI: InChI=1S/C52H76N12O10S2/c1-4-74-34-19-17-33(18-20-34)26-36-45(68)60-37(25-32-13-7-5-8-14-32)47(70)63-43(31(2)3)49(72)61-38(27-41(53)65)46(69)62-39(29-75-30-76-52(28-42(66)58-36)21-9-6-10-22-52)50(73)64-24-12-16-40(64)48(71)59-35(44(54)67)15-11-23-57-51(55)56/h5,7-8,13-14,17-20,31,35-40,43H,4,6,9-12,15-16,21-30H2,1-3H3,(H2,53,65)(H2,54,67)(H,58,66)(H,59,71)(H,60,68)(H,61,72)(H,62,69)(H,63,70)(H4,55,56,57)/t35-,36+,37+,38+,39+,40-,43-/m0/s1
Standard InChI Key: NRNNNNZZQZCNND-OOFXSPGDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1093.39 | Molecular Weight (Monoisotopic): 1092.5249 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Callahan JF, Ashton-Shue D, Bryan HG, Bryan WM, Heckman GD, Kinter LB, McDonald JE, Moore ML, Schmidt DB, Silvestri JS.. (1989) Structure-activity relationships of novel vasopressin antagonists containing C-terminal diaminoalkanes and (aminoalkyl)guanidines., 32 (2): [PMID:2521519] [10.1021/jm00122a017] |
Source(1):